GSPT1: A New Hope for Tumor Therapy

GSPT1

GSPT1: A New Hope for Tumor Therapy

In the field of tumor therapy, GSPT1 (G1 to S phase transition 1) is emerging as a new research focus. GSPT1, a critical translation termination factor, is closely associated with the occurrence and progression of various cancers due to its abnormal expression in tumor cells. The development of drugs targeting GSPT1 has brought new ideas and hope for tumor treatment.

GSPT1: A New Target for Tumor Therapy

GSPT1 (G1 to S phase transition 1) is a translation termination factor that interacts with eRF1 to recognize termination codons on mRNA, promoting the release of proteins from ribosomes. This process is crucial for the regulation of the cell cycle, particularly during the transition from the G1 to the S phase. Studies have found that GSPT1 expression levels are abnormally elevated in various tumor cells, and its upregulation is directly related to poor prognosis. Therefore, GSPT1 is not only an important cell cycle regulator but also a potential target for tumor therapy.

Advances in the Development of GSPT1-Targeted Drugs

In recent years, significant progress has been made in the development of GSPT1-targeted drugs with the advancement of targeted protein degradation technology. Currently, various GSPT1-targeted drugs have entered clinical research stages globally. These drugs mainly achieve GSPT1 degradation through technologies such as molecular glues and antibody-drug conjugates (DACs).

Molecular Glues

Molecular glues are small molecule compounds that can induce protein degradation by recruiting E3 ubiquitin ligase complexes, thereby promoting the ubiquitination and degradation of target proteins. MRT-2359, developed by Monte Rosa Therapeutics, is a highly selective GSPT1-targeted molecular glue degrader that has entered clinical trials. MRT-2359 leads to the degradation of GSPT1 protein by guiding the interaction between E3 ubiquitin ligase and GSPT1, thereby inhibiting tumor cell proliferation. Preclinical studies have shown that MRT-2359 exhibits good anticancer activity and safety in various tumor models. Additionally, CC-90009 and SJ6986 are also GSPT1-selective immunomodulatory drugs currently undergoing clinical trials.

Antibody-Drug Conjugates (DACs)

Antibody-drug conjugates (DACs) combine the targeting capability of antibodies with the degradation ability of degraders, enabling more precise delivery of degraders to tumor cells. ORM-5029, developed by Orum Therapeutics, is the world's first GSPT1-targeted DAC to enter clinical trials. Its antibody component is the HER2 antibody pertuzumab, and its payload is the GSPT1 degrader SMol006. Preclinical data has shown that ORM-5029 exhibits significant cytotoxicity in HER2-positive tumor cell lines and is more effective than single-agent GSPT1 degraders and traditional ADC drugs. Currently, ORM-5029 is undergoing Phase I clinical trials to evaluate its safety and efficacy in patients with HER2-positive advanced solid tumors.

Youai GSPT1 Protein: Bridging Research and Clinical Practice

Youai is committed to providing researchers with high-quality GSPT1 protein to support in-depth research into its role in tumor regulation. Youai's GSPT1 protein undergoes rigorous purification, ensuring high activity and strong specificity. It is suitable for various experimental scenarios and meets diverse experimental needs.

Available Products: